Navigation Links
MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
Date:8/20/2013

orthopedic complaints relating to the foot. In fact, it affects more than one million U.S. patients each year.  Plantar fasciitis is extremely challenging and frustrating for both patients and clinicians," added Petit.

Bill Taylor, President and COO, stated, "We believe the use of, AmnioFix®, our dHACM allograft injection, is an effective treatment for patients with inflammation associated with chronic plantar fasciitis and may reduce costs by decreasing the need for repeat office visits or costly surgical interventions. The standard of care management of plantar fasciitis leads to resolution of symptoms in many patients, although several months to even years of treatment are often required. A treatment that reduces inflammation and promotes the healing of soft tissue, allowing for rapid return to activities of daily living has been highly sought after. We believe the use of our dHACM allograft fulfills this need in the market for a rapidly effective treatment for patients with inflammation associated with chronic plantar fasciitis."

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION&
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
2. MiMedx Group Completes $5,000,000 Private Placement
3. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
4. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
5. MiMedx Group Announces 2011 Results
6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
7. MiMedx Exceeds Revenue Goal for First Quarter of 2012
8. MiMedx Group Announces Record First Quarter Results
9. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
10. MiMedx Group Announces Record Second Quarter Results
11. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The ability ... a culture that will allow individuals to perform at ... increasingly important for employers looking to compete in this ... are embracing this trend, as the sector increasingly focuses ... a company, which will have real results on the ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... 2008 Diffusion,Pharmaceuticals LLC, a clinical-stage drug-development ... action that enhances,oxygen diffusion, today announced that ... entitled "Bipolar Trans Carotenoid Salts and Their ... of first-in-class new chemical entities,known as trans ...
... Mass., April 8, 2008 Caliper Life,Sciences, Inc. (Nasdaq: ... Meeting,of Stockholders will be held on June 3, 2008, ... 68 Elm Street, Hopkinton, Massachusetts. The record,date for Caliper ... 16,2008., About Caliper Life Sciences, Caliper Life ...
... pain reliever lands its first national retail drug ... ... ALCiS Health, Inc., a,provider of patented pain relief products, today announced ... cream, ALCiS Daily Relief, at all of its 6,237 stores.,Its introduction onto ...
Cached Biology Technology:Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled 'Bipolar Trans Carotenoid Salts and Their Uses,' for Its Family of First-In-Class Molecules 2ALCiS(R) Daily Relief Now Available at Walgreens 2
(Date:9/1/2014)... An increasing amount of research shows an association between ... sedentary lifestyle. Now, a new Cornell University study points ... programs might lead people to eat twice as much ... an action movie while snacking your mouth will see ... on the new article just published in the ...
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... The quality of the U.S. diet showed some modest ... of a reduction in the consumption of unhealthy trans ... between the rich and the poor. , , An ... and some cancers. Eating a healthy diet is an ... outcomes. Evaluating population trends in diet quality is important ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... a Global Information System will provide valuable information for ... Institute of Environmental Health Sciences (NIEHS), one of the ... the most up-to-date data to public health and safety ... maps, as well as demographic information for local populations. ...
... Some 12.3 percent of all babies -- 499,008 infants -- ... according to the report released by the National Center for ... 480,000 babies) in 2002 -- and an increase of more ... in 1981. The prematurity rate was 9.4 in 1981; it ...
... the world's vaccine manufacturers will be in a race ... a new technique to more efficiently produce the disarmed ... vaccine in large quantities, life-saving inoculations may be available ... as governments worldwide prepare for a predicted pandemic of ...
Cached Biology News:NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina 2UW scientists report a new method to speed bird flu vaccine production 2UW scientists report a new method to speed bird flu vaccine production 3
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Biology Products: